Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.69 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.49 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375676 | 1.00 | S1PR1 (0.69) | S1PR1LTA4HTAOK1TAOK3NPY5R | |
| SCHEMBL1376155 | 0.88 | S1PR1 (0.73) | S1PR1LTA4HTAOK1TAOK3NPY5R | |
| SCHEMBL2365173 | 0.86 | S1PR1 (0.74) | S1PR1LTA4HTAOK1TAOK3SMN1; SMN2 | |
| SCHEMBL12044808 | 0.86 | S1PR1 (0.73) | S1PR1TAOK1TAOK3SMN1; SMN2RAB9A | |
| SCHEMBL13392751 | 0.86 | S1PR1 (0.73) | S1PR1LTA4HTAOK1TAOK3SMN1; SMN2 | |
| SCHEMBL13392723 | 0.85 | S1PR1 (0.62) | S1PR1LTA4HNPY5RSMN1; SMN2HPGD | |
| SCHEMBL2353153 | 0.85 | S1PR1 (0.72) | S1PR1TAOK1TAOK3SMN1; SMN2NPC1 | |
| SCHEMBL1374371 | 0.84 | S1PR1 (0.68) | S1PR1LTA4HTAOK1TAOK3 | |
| SCHEMBL1373528 | 0.84 | S1PR1 (0.68) | S1PR1LTA4HTAOK1TAOK3SMN1; SMN2 | |
| SCHEMBL1372559 | 0.84 | S1PR1 (0.68) | S1PR1LTA4HTAOK1TAOK3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| CN-102256944-A | Sphingosine-1-phosphate receptor antagonists | EXELIXIS INC | 2011-11-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885LTA4H 1113/4885TAOK1 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.